ClariVest Asset Management LLC grew its position in Haemonetics Co. (NYSE:HAE) by 46.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 89,968 shares of the medical instruments supplier’s stock after purchasing an additional 28,392 shares during the quarter. ClariVest Asset Management LLC’s holdings in Haemonetics were worth $9,002,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in HAE. Vanguard Group Inc. grew its holdings in shares of Haemonetics by 1.9% during the third quarter. Vanguard Group Inc. now owns 5,619,707 shares of the medical instruments supplier’s stock valued at $643,906,000 after buying an additional 107,357 shares during the last quarter. Vanguard Group Inc grew its holdings in shares of Haemonetics by 1.9% during the third quarter. Vanguard Group Inc now owns 5,619,707 shares of the medical instruments supplier’s stock valued at $643,906,000 after buying an additional 107,357 shares during the last quarter. Renaissance Technologies LLC grew its holdings in shares of Haemonetics by 14.6% during the third quarter. Renaissance Technologies LLC now owns 2,256,500 shares of the medical instruments supplier’s stock valued at $258,550,000 after buying an additional 286,800 shares during the last quarter. Jackson Square Partners LLC grew its holdings in shares of Haemonetics by 15.6% during the third quarter. Jackson Square Partners LLC now owns 1,439,167 shares of the medical instruments supplier’s stock valued at $164,899,000 after buying an additional 194,045 shares during the last quarter. Finally, American Century Companies Inc. grew its holdings in shares of Haemonetics by 231.1% during the third quarter. American Century Companies Inc. now owns 1,005,784 shares of the medical instruments supplier’s stock valued at $115,243,000 after buying an additional 701,976 shares during the last quarter. 97.54% of the stock is currently owned by institutional investors and hedge funds.
In other Haemonetics news, VP Dan Goldstein sold 1,693 shares of the company’s stock in a transaction on Monday, December 10th. The shares were sold at an average price of $102.91, for a total value of $174,226.63. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Richard J. Meelia sold 8,196 shares of the company’s stock in a transaction on Friday, December 14th. The shares were sold at an average price of $102.86, for a total transaction of $843,040.56. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 10,916 shares of company stock worth $1,124,301. 1.04% of the stock is owned by corporate insiders.
Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Tuesday, February 5th. The medical instruments supplier reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.59 by $0.04. The firm had revenue of $247.36 million for the quarter, compared to analyst estimates of $250.12 million. Haemonetics had a net margin of 4.84% and a return on equity of 17.05%. The business’s quarterly revenue was up 5.7% compared to the same quarter last year. During the same period in the previous year, the company earned $0.62 earnings per share. Sell-side analysts anticipate that Haemonetics Co. will post 2.33 EPS for the current fiscal year.
A number of equities research analysts have recently weighed in on HAE shares. ValuEngine lowered shares of Haemonetics from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 5th. Zacks Investment Research raised shares of Haemonetics from a “sell” rating to a “hold” rating in a report on Wednesday, January 30th. Finally, Barrington Research boosted their price objective on shares of Haemonetics to $112.00 and gave the company a “positive” rating in a report on Wednesday, February 6th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Haemonetics has an average rating of “Buy” and an average price target of $119.75.
COPYRIGHT VIOLATION WARNING: “ClariVest Asset Management LLC Has $9 Million Holdings in Haemonetics Co. (HAE)” was reported by Dakota Financial News and is the sole property of of Dakota Financial News. If you are viewing this story on another site, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this story can be read at https://dakotafinancialnews.com/2019/02/12/clarivest-asset-management-llc-has-9-million-holdings-in-haemonetics-co-hae.html.
Haemonetics Company Profile
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.
See Also: Channel Trading
Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Co. (NYSE:HAE).
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.